Nicole Adams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nicole Adams has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Aria Eshraghi
Department of Infectious Diseases & Immunology, University of Florida, United States
6 shared publications - Nimra Khalid
Department of Infectious Diseases & Immunology, University of Florida, Gainesville, Florida, USA
3 shared publications - Alexis Irvin
Department of Infectious Diseases & Immunology, University of Florida , Gainesville, Florida, USA
2 shared publications Alyssa Walker
Microbiology and Cell Science Department, Institute of Food and Agricultural Sciences, University of Florida
2 shared publications- Daniel M. Czyz
Microbiology and Cell Science Department, Institute of Food and Agricultural Sciences, University of Florida
2 shared publications - Danielle Hulvey
University of Florida
2 shared publications
Latest Publications
- Open Access
- 1 November 2025
- Published by American Dairy Science Association in JDS Communications
- Vol. 6 (6) , 816-821
The microdrip method rapidly and efficiently enumerates bacterial colony-forming units in bovine milk
Summary: Investigating bacterially induced experimental mastitis requires reliable, precise, and reproducible enumeration of viable bacteria in milk. Standard microbiological methods to enumerate colony-forming units (cfu) are time consuming and expensive. In this work, we describe a microdrip method of cfu enumeration that not only reduces cost and time, but is also less variable, has increased reproducibility, and accommodates plating a greater number of technical replicates compared with standard bacterial enumeration methods. This suggests that the microdrip method is superior, considering statistical and practical considerations.
- 1 November 2025
- Published by American Dairy Science Association in JDS Communications
- Vol. 6 (6) , 816-821
Open AccessThe microdrip method rapidly and efficiently enumerates bacterial colony-forming units in bovine milk
Summary: Investigating bacterially induced experimental mastitis requires reliable, precise, and reproducible enumeration of viable bacteria in milk. Standard microbiological methods to enumerate colony-forming units (cfu) are time consuming and expensive. In this work, we describe a microdrip method of cfu enumeration that not only reduces cost and time, but is also less variable, has increased reproducibility, and accommodates plating a greater number of technical replicates compared with standard bacterial enumeration methods. This suggests that the microdrip method is superior, considering statistical and practical considerations.
- Open Access
- 8 October 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (10) , e0031225
Targeting deubiquitinating enzymes and ubiquitin pathway modulators to enhance host defense against bacterial infections
The rise of antibiotic-resistant bacterial pathogens poses a critical global health challenge, necessitating innovative therapeutic strategies. This study explores host-targeted therapies by focusing on deubiquitinating enzymes (DUBs), key regulators of the ubiquitin-proteasome system (UPS) that mediate host-pathogen interactions. Using Salmonella -infected macrophages, we screened a UPS-targeted compound library and identified several compounds that enhanced bacterial clearance without affecting host cell viability. Among these, the dual USP25/USP28 inhibitor AZ-1 emerged as one of the top candidates. Transcriptomic profiling revealed infection-induced upregulation of DUBs, particularly USP25, USP46, and OTUD7B. USP25 knockdown significantly reduced intracellular Salmonella , confirming its role as a critical host factor. AZ-1 also exhibited broad-spectrum intracellular activity against multidrug-resistant Pseudomonas aeruginosa , Klebsiella pneumoniae , and Acinetobacter baumannii . In vivo , AZ-1 reduced fecal bacterial loads, clinical scores, and infection-induced weight loss, though it did not extend survival. AZ-1 had no direct antibacterial activity in axenic culture, indicating a host-targeting mechanism. Transcriptomic and signaling analyses revealed AZ-1 suppressed key immune pathways, including nuclear factor-kappa B (NF-κB) signaling. These findings establish DUBs as promising targets for host-directed therapies and support further development of UPS-targeted agents to combat antimicrobial resistance. IMPORTANCE: Antibiotic-resistant infections, particularly those caused by intracellular pathogens, represent an urgent public health threat due to their ability to evade immune responses and resist conventional antibiotics. This study identifies the ubiquitin-proteasome system, specifically deubiquitinating enzymes, as viable targets for host-directed therapy. We demonstrate that the USP25/USP28 inhibitor AZ-1 enhances intracellular bacterial clearance without compromising host cell viability and is effective against several multidrug-resistant gram-negative pathogens. Knockdown of USP25 alone also reduced intracellular Salmonella , stressing out its proposed role in bacterial persistence. AZ-1 improved early infection outcomes in vivo but was insufficient as monotherapy. These findings support a novel therapeutic approach that targets host pathways to enhance bacterial clearance, offering a promising adjunct to traditional antibiotics in the fight against antimicrobial resistance.
- 8 October 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (10) , e0031225
Open AccessTargeting deubiquitinating enzymes and ubiquitin pathway modulators to enhance host defense against bacterial infections
The rise of antibiotic-resistant bacterial pathogens poses a critical global health challenge, necessitating innovative therapeutic strategies. This study explores host-targeted therapies by focusing on deubiquitinating enzymes (DUBs), key regulators of the ubiquitin-proteasome system (UPS) that mediate host-pathogen interactions. Using Salmonella -infected macrophages, we screened a UPS-targeted compound library and identified several compounds that enhanced bacterial clearance without affecting host cell viability. Among these, the dual USP25/USP28 inhibitor AZ-1 emerged as one of the top candidates. Transcriptomic profiling revealed infection-induced upregulation of DUBs, particularly USP25, USP46, and OTUD7B. USP25 knockdown significantly reduced intracellular Salmonella , confirming its role as a critical host factor. AZ-1 also exhibited broad-spectrum intracellular activity against multidrug-resistant Pseudomonas aeruginosa , Klebsiella pneumoniae , and Acinetobacter baumannii . In vivo , AZ-1 reduced fecal bacterial loads, clinical scores, and infection-induced weight loss, though it did not extend survival. AZ-1 had no direct antibacterial activity in axenic culture, indicating a host-targeting mechanism. Transcriptomic and signaling analyses revealed AZ-1 suppressed key immune pathways, including nuclear factor-kappa B (NF-κB) signaling. These findings establish DUBs as promising targets for host-directed therapies and support further development of UPS-targeted agents to combat antimicrobial resistance. IMPORTANCE: Antibiotic-resistant infections, particularly those caused by intracellular pathogens, represent an urgent public health threat due to their ability to evade immune responses and resist conventional antibiotics. This study identifies the ubiquitin-proteasome system, specifically deubiquitinating enzymes, as viable targets for host-directed therapy. We demonstrate that the USP25/USP28 inhibitor AZ-1 enhances intracellular bacterial clearance without compromising host cell viability and is effective against several multidrug-resistant gram-negative pathogens. Knockdown of USP25 alone also reduced intracellular Salmonella , stressing out its proposed role in bacterial persistence. AZ-1 improved early infection outcomes in vivo but was insufficient as monotherapy. These findings support a novel therapeutic approach that targets host pathways to enhance bacterial clearance, offering a promising adjunct to traditional antibiotics in the fight against antimicrobial resistance.
- Open Access
Targeting deubiquitinating enzymes (DUBs) and ubiquitin pathway modulators to enhance host defense against bacterial infections
The rise of antibiotic-resistant bacterial pathogens poses a critical global health challenge, necessitating innovative therapeutic approaches. This study explores host-targeted therapies (HTTs) by focusing on deubiquitinating enzymes (DUBs), essential modulators of the ubiquitin-proteasome system (UPS) that regulate host-pathogen interactions during many bacterial infections. Using Salmonella-infected macrophages as a model, we identified UPS modulators that enhance bacterial clearance and observed significant changes in DUB expression, particularly USP25, USP46, and Otud7b. The small-molecule DUB inhibitor AZ-1 significantly reduced intracellular bacterial loads in vitro and mitigated early disease severity in a murine model by decreasing fecal bacterial loads and preserving host weight. However, AZ-1 alone did not achieve complete clearance of Salmonella and required combination with extracellular-targeting antibiotics for optimal efficacy. Notably, AZ-1 demonstrated broad-spectrum activity against multidrug-resistant pathogens, including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. Transcriptomic analyses revealed infection-induced DUB regulation and highlighted pathways modulating immune responses, including TNF-α secretion. These findings highlight the potential of targeting the UPS as a host-directed antimicrobial strategy and provide a foundation for developing innovative therapies to combat antimicrobial resistance.
Open AccessTargeting deubiquitinating enzymes (DUBs) and ubiquitin pathway modulators to enhance host defense against bacterial infections
The rise of antibiotic-resistant bacterial pathogens poses a critical global health challenge, necessitating innovative therapeutic approaches. This study explores host-targeted therapies (HTTs) by focusing on deubiquitinating enzymes (DUBs), essential modulators of the ubiquitin-proteasome system (UPS) that regulate host-pathogen interactions during many bacterial infections. Using Salmonella-infected macrophages as a model, we identified UPS modulators that enhance bacterial clearance and observed significant changes in DUB expression, particularly USP25, USP46, and Otud7b. The small-molecule DUB inhibitor AZ-1 significantly reduced intracellular bacterial loads in vitro and mitigated early disease severity in a murine model by decreasing fecal bacterial loads and preserving host weight. However, AZ-1 alone did not achieve complete clearance of Salmonella and required combination with extracellular-targeting antibiotics for optimal efficacy. Notably, AZ-1 demonstrated broad-spectrum activity against multidrug-resistant pathogens, including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. Transcriptomic analyses revealed infection-induced DUB regulation and highlighted pathways modulating immune responses, including TNF-α secretion. These findings highlight the potential of targeting the UPS as a host-directed antimicrobial strategy and provide a foundation for developing innovative therapies to combat antimicrobial resistance.
- Open Access
Pathogenicity determinant protein E is a Francisella type VI secretion system effector protein that modulates host death
Francisella tularensis is a highly pathogenic Gram-negative intracellular bacterial pathogen and the etiologic agent of tularemia, a fatal zoonotic disease that poses a threat to global public health. F. tularensis virulence is mediated by genes on the Francisella pathogenicity island (FPI), which encodes a unique contractile secretion apparatus with functional and structural similarity to bacterial type VI secretion systems (T6SSs). T6SSs can inject effector proteins into host cells to facilitate invasion, intracellular proliferation, and pathogenesis; however, the identity and function of Francisella effectors are still unclear. In this study, we measured T6SS activity in a series of FPI deletion mutants to identify genes that are required for core apparatus activity. We found that Pathogenicity Determinant Protein E (PdpE) is not required for secretion of T6SS substrates or intramacrophage growth. Instead, PdpE forms a complex with another T6SS-secreted effector, PdpC, and limits death of infected host cells by attenuating the macrophage type I interferon response. Importantly, a Δ pdpE mutant more rapidly induces death in an established invertebrate in vivo model for Francisella infection. These data define the role of a previously uncharacterized substrate of the Francisella T6SS and provide new insights into host- Francisella interaction.
Open AccessPathogenicity determinant protein E is a Francisella type VI secretion system effector protein that modulates host death
Francisella tularensis is a highly pathogenic Gram-negative intracellular bacterial pathogen and the etiologic agent of tularemia, a fatal zoonotic disease that poses a threat to global public health. F. tularensis virulence is mediated by genes on the Francisella pathogenicity island (FPI), which encodes a unique contractile secretion apparatus with functional and structural similarity to bacterial type VI secretion systems (T6SSs). T6SSs can inject effector proteins into host cells to facilitate invasion, intracellular proliferation, and pathogenesis; however, the identity and function of Francisella effectors are still unclear. In this study, we measured T6SS activity in a series of FPI deletion mutants to identify genes that are required for core apparatus activity. We found that Pathogenicity Determinant Protein E (PdpE) is not required for secretion of T6SS substrates or intramacrophage growth. Instead, PdpE forms a complex with another T6SS-secreted effector, PdpC, and limits death of infected host cells by attenuating the macrophage type I interferon response. Importantly, a Δ pdpE mutant more rapidly induces death in an established invertebrate in vivo model for Francisella infection. These data define the role of a previously uncharacterized substrate of the Francisella T6SS and provide new insights into host- Francisella interaction.
- 2 October 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (11) , 3902-3914
Tolfenpyrad Derivatives Exhibit Potent Francisella-Specific Antibacterial Activity without Toxicity to Mammalian Cells In Vitro
Tularemia is a deadly disease caused by Francisella tularensis, an emerging intracellular bacterial pathogen that can be disseminated rapidly through aerosols and vector-borne transmission. Recent surveillance data demonstrate an increasing incidence in several countries. Although clinical isolates of Francisella strains are sensitive to currently used antibiotics, engineered or horizontal acquisition of antibiotic resistance is a constant threat to public health. Therefore, the identification of antibiotics that target previously undrugged pathways is required to safeguard human health. An environmental pesticide that is registered for use in multiple countries, tolfenpyrad, shows promising activity to block Francisella growth; however, it is not a suitable antimicrobial candidate for use in vivo due to potential toxicity in humans and other animals. In this study, we applied a structure-activity relationship approach to tolfenpyrad to generate compounds with improved antibacterial activity and reduced toxicity. Through screening of a library of derivatives, we identified analogs with improved therapeutic windows compared with tolfenpyrad. Although structural diversity exists among these analogs, they inhibit the growth of Francisella species but not other Gram-negative or Gram-positive species. These compounds block intramacrophage growth of F. novicida and pathogenesis in an in vivo arthropod model of infection. Although the biochemical activity of these drugs is unknown, they appear to target the same pathway as the parent molecule because F. novicida mutants that are resistant to tolfenpyrad are also resistant to its analogs. Taken together, these findings suggest that these tolfenpyrad-derived compounds comprise a new class of Francisella-targeted antimicrobials and merit further evaluation and development.
- 2 October 2024
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 10 (11) , 3902-3914
Tolfenpyrad Derivatives Exhibit Potent Francisella-Specific Antibacterial Activity without Toxicity to Mammalian Cells In Vitro
Tularemia is a deadly disease caused by Francisella tularensis, an emerging intracellular bacterial pathogen that can be disseminated rapidly through aerosols and vector-borne transmission. Recent surveillance data demonstrate an increasing incidence in several countries. Although clinical isolates of Francisella strains are sensitive to currently used antibiotics, engineered or horizontal acquisition of antibiotic resistance is a constant threat to public health. Therefore, the identification of antibiotics that target previously undrugged pathways is required to safeguard human health. An environmental pesticide that is registered for use in multiple countries, tolfenpyrad, shows promising activity to block Francisella growth; however, it is not a suitable antimicrobial candidate for use in vivo due to potential toxicity in humans and other animals. In this study, we applied a structure-activity relationship approach to tolfenpyrad to generate compounds with improved antibacterial activity and reduced toxicity. Through screening of a library of derivatives, we identified analogs with improved therapeutic windows compared with tolfenpyrad. Although structural diversity exists among these analogs, they inhibit the growth of Francisella species but not other Gram-negative or Gram-positive species. These compounds block intramacrophage growth of F. novicida and pathogenesis in an in vivo arthropod model of infection. Although the biochemical activity of these drugs is unknown, they appear to target the same pathway as the parent molecule because F. novicida mutants that are resistant to tolfenpyrad are also resistant to its analogs. Taken together, these findings suggest that these tolfenpyrad-derived compounds comprise a new class of Francisella-targeted antimicrobials and merit further evaluation and development.
- Open Access
- 12 December 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (6) , e0271323
Tolfenpyrad displays Francisella -targeted antibiotic activity that requires an oxidative stress response regulator for sensitivity
Francisella tularensis is a highly infectious Gram-negative bacterial pathogen capable of animal-to-human transmission. Due to its remarkable pathogenicity and potential for widespread public health impact, F. tularensis is classified as a high-priority pathogen by the Centers for Disease Control and Prevention. The historical development of Francisella as a bioweapon, coupled with the ease of engineering antibiotic-resistant strains, has spurred interest in the discovery of novel antibiotics. A library of drug-like compounds was screened for their ability to inhibit the growth of Francisella novicida , a biosafety level-2 surrogate for F. tularensis . Tolfenpyrad, a pesticide without previously identified antibacterial activity, was among the most potent inhibitors. Tolfenpyrad appears to uniquely target Francisella , as related species were sensitive, whereas bacteria in other genera were resistant. To identify Francisella pathways conferring sensitivity to tolfenpyrad, whole-genome sequencing of tolfenpyrad-resistant isolates was performed. Point mutations in two genes conferred resistance to osrR, a transcriptional regulator, and nuoM, a subunit of the electron transport chain. OsrR point mutants displayed attenuated growth in interferon gamma (IFN-γ)-stimulated macrophages but not in untreated macrophages, indicating that OsrR plays a role in resistance to IFN-γ-stimulated clearance of intracellular bacteria. OsrR point mutants are hypersensitive to reactive oxygen species, suggesting a mechanism by which they are rapidly cleared from IFN-γ-treated macrophages. This work identifies a novel Francisella -specific antibiotic activity and the metabolic pathways targeted. Moreover, we provide amino acid-level details of a Francisella protein that governs sensitivity to free radicals. IMPORTANCE: Francisella species are highly pathogenic bacteria that pose a threat to global health security. These bacteria can be made resistant to antibiotics through facile methods, and we lack a safe and protective vaccine. Given their history of development as bioweapons, new treatment options must be developed to bolster public health preparedness. Here, we report that tolfenpyrad, a pesticide that is currently in use worldwide, effectively inhibits the growth of Francisella . This drug has an extensive history of use and a plethora of safety and toxicity data, making it a good candidate for development as an antibiotic. We identified mutations in Francisella novicida that confer resistance to tolfenpyrad and characterized a transcriptional regulator that is required for sensitivity to both tolfenpyrad and reactive oxygen species.
- 12 December 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (6) , e0271323
Open AccessTolfenpyrad displays Francisella -targeted antibiotic activity that requires an oxidative stress response regulator for sensitivity
Francisella tularensis is a highly infectious Gram-negative bacterial pathogen capable of animal-to-human transmission. Due to its remarkable pathogenicity and potential for widespread public health impact, F. tularensis is classified as a high-priority pathogen by the Centers for Disease Control and Prevention. The historical development of Francisella as a bioweapon, coupled with the ease of engineering antibiotic-resistant strains, has spurred interest in the discovery of novel antibiotics. A library of drug-like compounds was screened for their ability to inhibit the growth of Francisella novicida , a biosafety level-2 surrogate for F. tularensis . Tolfenpyrad, a pesticide without previously identified antibacterial activity, was among the most potent inhibitors. Tolfenpyrad appears to uniquely target Francisella , as related species were sensitive, whereas bacteria in other genera were resistant. To identify Francisella pathways conferring sensitivity to tolfenpyrad, whole-genome sequencing of tolfenpyrad-resistant isolates was performed. Point mutations in two genes conferred resistance to osrR, a transcriptional regulator, and nuoM, a subunit of the electron transport chain. OsrR point mutants displayed attenuated growth in interferon gamma (IFN-γ)-stimulated macrophages but not in untreated macrophages, indicating that OsrR plays a role in resistance to IFN-γ-stimulated clearance of intracellular bacteria. OsrR point mutants are hypersensitive to reactive oxygen species, suggesting a mechanism by which they are rapidly cleared from IFN-γ-treated macrophages. This work identifies a novel Francisella -specific antibiotic activity and the metabolic pathways targeted. Moreover, we provide amino acid-level details of a Francisella protein that governs sensitivity to free radicals. IMPORTANCE: Francisella species are highly pathogenic bacteria that pose a threat to global health security. These bacteria can be made resistant to antibiotics through facile methods, and we lack a safe and protective vaccine. Given their history of development as bioweapons, new treatment options must be developed to bolster public health preparedness. Here, we report that tolfenpyrad, a pesticide that is currently in use worldwide, effectively inhibits the growth of Francisella . This drug has an extensive history of use and a plethora of safety and toxicity data, making it a good candidate for development as an antibiotic. We identified mutations in Francisella novicida that confer resistance to tolfenpyrad and characterized a transcriptional regulator that is required for sensitivity to both tolfenpyrad and reactive oxygen species.